U.S. Media Stock News

NYSE:MTG
NYSE:MTGDiversified Financial

A Look At MGIC Investment (MTG) Valuation After Recent Share Price Consolidation

Why MGIC Investment (MTG) Is On Investors’ Radar Today MGIC Investment (MTG) is drawing attention after recent trading left the mortgage insurer’s shares roughly flat over the past month, with a modest loss over the past 3 months and a decline year to date. See our latest analysis for MGIC Investment. At a share price of US$26.53, MGIC Investment’s short term share price return over the past 90 days has been negative, while its 1 year and 5 year total shareholder returns remain firmly...
NYSE:HPP
NYSE:HPPOffice REITs

Hudson Pacific Properties (HPP) FFO Hovering Near Breakeven Challenges Bearish Narratives

Hudson Pacific Properties (HPP) closed out FY 2025 with Q4 revenue of US$256.0 million and basic EPS of US$4.31 loss, while trailing twelve month revenue came in at US$831.1 million alongside a TTM basic EPS of US$12.81 loss. This gives investors a clear snapshot of pressure on per share results. Over recent periods, the company has seen quarterly revenue shift from US$208.8 million in Q4 2024 to US$256.0 million in Q4 2025, with basic EPS moving from a loss of US$8.28 per share to a loss of...
NYSE:DK
NYSE:DKOil and Gas

Delek US Holdings (DK) Posts Q4 Profit While TTM Loss Keeps Bearish Narrative Intact

Delek US Holdings (DK) closed out FY 2025 with Q4 revenue of US$2,429.4 million and basic EPS of US$1.32, alongside net income from continuing operations of US$79.5 million. Over the past few quarters, revenue has moved between US$2,641.9 million and US$2,887 million while basic EPS has swung from a loss of US$2.78 in Q1 2025 to a profit of US$2.96 in Q3 2025 and then US$1.32 in Q4, highlighting the sensitivity of margins to refining conditions and product mix. See our full analysis for Delek...
NasdaqGS:CCCC
NasdaqGS:CCCCBiotechs

C4 Therapeutics (CCCC) Quarterly Loss Narrows To US$20.5m Challenging Persistent Bearish Narratives

C4 Therapeutics (CCCC) just posted its FY 2025 Q4 numbers, with revenue of US$11.0 million and a quarterly loss translating to basic EPS of US$0.18, set against a trailing twelve month loss of US$105.0 million and EPS of US$1.27 on revenue of US$35.9 million. Over recent quarters, the company has seen revenue move between US$5.2 million and US$15.4 million, while quarterly EPS has ranged from US$0.35 to US$0.49 and quarterly losses from US$24.7 million to US$34.6 million. The key question for...
NYSE:CI
NYSE:CIHealthcare

Cigna Group (CI) Margin Improvement To 2.2% Challenges Skeptical Earnings Narratives

Cigna Group (CI) has wrapped up FY 2025 with fourth quarter revenue of US$72.5b, basic EPS of US$4.67 and net income of US$1,234m, putting a clear spotlight on how the year’s strong headline numbers translate into underlying profitability. The company has seen quarterly revenue move from US$65.6b in Q4 2024 to US$72.5b in Q4 2025, with basic EPS shifting from US$5.13 to US$4.67 over the same period. Trailing 12 month EPS reached US$22.33 on net income of US$5,957m, highlighting a year in...
NasdaqGM:GDEN
NasdaqGM:GDENHospitality

Golden Entertainment (GDEN) Loss Deepens In Q4 EPS Miss Challenges Profit-Recovery Narrative

Golden Entertainment (GDEN) has wrapped up FY 2025 with Q4 revenue of US$155.6 million and a basic EPS loss of US$0.33, alongside net income excluding extra items of a US$8.5 million loss. Over recent periods, the company has seen quarterly revenue move between US$154.8 million and US$164.2 million, while EPS has swung from a profit of US$0.18 in Q3 2024 to a loss of US$0.33 in Q4 2025. This leaves investors watching how quickly margins can stabilize from here. See our full analysis for...
NasdaqGM:CSTL
NasdaqGM:CSTLHealthcare

Castle Biosciences (CSTL) Q4 EPS Loss Tests Bullish Profitability Narrative

Castle Biosciences (CSTL) has wrapped up FY 2025 with Q4 revenue of US$87 million and a basic EPS loss of US$0.08, alongside trailing twelve month revenue of US$344.2 million and a basic EPS loss of US$0.83. Over recent periods, the company has seen quarterly revenue range from US$83 million to US$88 million, while basic EPS has moved between a loss of US$0.90 and a profit of US$0.16. This sets the stage for investors to focus closely on how those revenue levels translate into sustainable...
NYSE:GWW
NYSE:GWWTrade Distributors

Assessing W.W. Grainger (GWW) Valuation After Its Better Than Expected Earnings And Upgraded Outlook

What the latest earnings mean for W.W. Grainger (GWW) investors W.W. Grainger (GWW) recently posted quarterly results that topped expectations on both earnings and revenue, while management laid out full year guidance that points to higher projected EPS and sales compared with its latest reported figures. See our latest analysis for W.W. Grainger. At a share price of $1,144.73, W.W. Grainger has seen a 20.67% 90 day share price return and a 68.51% three year total shareholder return,...
NYSE:FIGS
NYSE:FIGSLuxury

FIGS (FIGS) Margin Rebound Reinforces Bullish Narratives Despite Premium 75.1x P/E

FIGS (FIGS) closed out FY 2025 with Q4 revenue of US$201.9 million and basic EPS of US$0.11, while trailing twelve month EPS sat at US$0.21 on US$631.1 million of revenue. This came alongside a very large year over year earnings increase and a trailing net profit margin of 5.4% versus 0.5% a year earlier. The company has seen quarterly revenue move from US$151.8 million and EPS of US$0.01 in Q4 2024 to US$201.9 million and EPS of US$0.11 in Q4 2025, putting improving profitability front and...
NYSE:WD
NYSE:WDDiversified Financial

Walker & Dunlop (WD) One Off Loss And Margin Compression Test Bullish Growth Narratives

Walker & Dunlop FY 2025 earnings snapshot Walker & Dunlop (WD) closed out FY 2025 with Q4 revenue of US$320.9 million and a basic EPS loss of US$0.39, as net income excluding extra items came in at a loss of US$13.1 million. The company reported quarterly revenue of US$321.0 million and EPS of US$1.32 in Q4 2024, compared with US$320.9 million and an EPS loss of US$0.39 in Q4 2025. Trailing twelve month revenue was US$1.2 billion and basic EPS was US$1.71. With margins under pressure and a...
NasdaqGS:ALHC
NasdaqGS:ALHCHealthcare

Alignment Healthcare (ALHC) Near Breakeven TTM Loss Tests Bullish Profitability Narratives

Alignment Healthcare (ALHC) has wrapped up FY 2025 with Q4 revenue of US$1.0b and a basic EPS loss of US$0.05, alongside trailing 12 month revenue of US$4.0b and a near breakeven basic EPS of US$0.00. The company has seen quarterly revenue move from US$701.2m and a basic EPS loss of US$0.16 in Q4 2024 to US$1.0b and a basic EPS loss of US$0.05 in Q4 2025, while trailing 12 month basic EPS shifted from a loss of US$0.67 in Q4 2024 to a small loss of US$0.00 in Q4 2025, putting the focus firmly...
NasdaqGS:CTKB
NasdaqGS:CTKBLife Sciences

Cytek Biosciences (CTKB) Q4 EPS Swing To Loss Reinforces Margin Concerns

Cytek Biosciences (CTKB) closed out FY 2025 with Q4 revenue of US$62.1 million and a basic EPS loss of US$0.34, as net income excluding extra items came in at a loss of US$44.1 million. The company has seen quarterly revenue range from US$41.5 million to US$62.1 million over the past year, while basic EPS moved from a profit of US$0.07 in Q4 2024 to a loss of US$0.34 in Q4 2025. This shift highlights a clear pressure point on profitability. For investors, the latest print keeps the focus...
NasdaqCM:RIOT
NasdaqCM:RIOTSoftware

Riot Platforms Earnings Beat Fuels Debate On Crypto Versus Operations

Riot Platforms reported revenues that exceeded consensus estimates. The company delivered an earnings surprise relative to market expectations. The results highlight operational performance that goes beyond price driven speculation. Riot Platforms, trading under NasdaqCM:RIOT, is drawing attention after its latest results, with revenue and earnings both coming in ahead of what the market had been expecting. The stock closed at $16.29, with a return of 15.0% year to date and 75.5% over the...
NasdaqGS:TRS
NasdaqGS:TRSPackaging

TriMas (TRS) Margin Jump Driven By One Off Gains Challenges Earnings Quality Narratives

TriMas (TRS) has wrapped up FY 2025 with fourth quarter revenue of US$155.5 million and basic EPS of US$1.84, while trailing twelve month EPS stands at US$1.79 on revenue of US$645.7 million and a net profit margin of 11.2% versus 2.6% a year earlier. Over recent periods, the company has seen quarterly revenue range from US$228.1 million in Q4 2024 to US$274.8 million in Q2 2025, with basic EPS moving from US$0.14 in Q4 2024 to US$0.41 in Q2 2025 and US$0.31 in Q1 2025. With earnings over the...
NYSE:XPOF
NYSE:XPOFHospitality

Xponential Fitness (XPOF) Q4 Loss Widening Tests Bullish Margin Recovery Narratives

Xponential Fitness (XPOF) just wrapped up FY 2025 with Q4 revenue of US$83.0 million, a basic EPS loss of US$0.93 and net income excluding extra items showing a loss of US$32.9 million. Over the past six quarters, the company has seen quarterly revenue move between US$76.2 million and US$83.8 million, while basic EPS ranged from a loss of US$0.01 to a loss of US$1.37. Trailing twelve month EPS stands at a loss of US$1.11 on revenue of US$314.9 million and a net loss excluding extra items of...
NasdaqCM:RKLB
NasdaqCM:RKLBAerospace & Defense

Rocket Lab (RKLB) Q4 Loss Of US$52.9 Million Tests Profitability Narratives

Rocket Lab (RKLB) has just put fresh numbers on the table for FY 2025, reporting Q4 revenue of US$179.7 million and a basic EPS loss of US$0.09, alongside trailing 12 month revenue of US$601.8 million and a full year EPS loss of US$0.37. The company’s quarterly revenue moved from US$132.4 million in Q4 2024 to US$179.7 million in Q4 2025, while quarterly EPS losses ranged between US$0.10 and US$0.13 across FY 2025. As a result, the focus for investors is on how quickly those losses can be...
NasdaqGM:OCUL
NasdaqGM:OCULPharmaceuticals

Is Ocular Therapeutix (OCUL) Pricing Reflecting Its Recent Volatility And DCF Implied Upside

Investors may be wondering whether Ocular Therapeutix at US$8.94 is starting to look interesting on price, or if the recent moves are already baking in the upside. The stock has been volatile lately, with a 14.9% gain over the last 7 days, a 13.0% decline over 30 days, a 24.4% decline year to date, a 25.2% return over 1 year, and 51.3% over 3 years, while still sitting 51.7% lower over 5 years. These swings have kept Ocular Therapeutix on the radar of investors watching for changing...
NasdaqGS:ICFI
NasdaqGS:ICFIProfessional Services

ICF International (ICFI) Margin Compression Challenges Long Term EPS Growth Narrative

ICF International (ICFI) closed out FY 2025 with Q4 revenue of US$443.7 million and basic EPS of US$0.95, alongside trailing twelve month revenue of about US$1.9 billion and EPS of US$5.0 that frame the latest print against a full year backdrop. Over recent quarters, the company has seen revenue move from US$516.9 million in Q3 2024 to US$487.6 million in Q1 2025 and US$443.7 million in Q4 2025, while basic EPS shifted from US$1.74 to US$1.45 and then to US$0.95. This sets up a results season...
NasdaqGS:GSAT
NasdaqGS:GSATTelecom

Globalstar (GSAT) Losses Narrow Sharply Which Reinforces Bullish Profitability Narratives

Globalstar (GSAT) has released its FY 2025 numbers, reporting Q4 revenue of US$72 million and a basic EPS loss of US$0.11. On a trailing twelve month basis, revenue came in at US$273 million and basic EPS was a loss of US$0.15. Over recent periods, the company has seen quarterly revenue range from US$60 million to US$74 million and basic EPS swing between a profit of US$0.13 and losses of up to US$0.42. This gives a clear view of how volatile margins have been as the business works through...
NYSE:CON
NYSE:CONHealthcare

Concentra Group (CON) Margin Compression Challenges Bullish Earnings Growth Narrative

Concentra Group Holdings Parent FY 2025 earnings snapshot Concentra Group Holdings Parent (CON) has wrapped up FY 2025 with Q4 revenue of US$539.1 million and basic EPS of US$0.28, capping off a year where trailing 12 month revenue reached about US$2.2 billion and EPS sat at US$1.30. The company has seen quarterly revenue move from US$465.0 million in Q4 2024 to US$539.1 million in Q4 2025, while basic EPS over that same Q4 stretch shifted from US$0.17 to US$0.28, setting up a situation where...
NYSE:BX
NYSE:BXCapital Markets

Is Blackstone (BX) Now Offering Value After Its Recent Share Price Pullback?

If you are wondering whether Blackstone is starting to look interesting at today's price, this article will walk through what the current market tag might be implying about its long term value. After reaching a last close of US$113.37, the stock has seen a 6.5% decline over the past week and a 22.8% decline over the past month, while still sitting on gains of 36.4% over 3 years and 103.7% over 5 years. Recent attention on Blackstone has been shaped by ongoing headlines around private...
NYSE:RLJ
NYSE:RLJHotel and Resort REITs

RLJ Lodging Trust (RLJ) FFO Volatility Tests Bullish Earnings Growth Narrative

RLJ Lodging Trust (RLJ) closed out FY 2025 with fourth quarter revenue of US$328.6 million and basic EPS of a US$0.04 loss, while the trailing twelve months show revenue of about US$1.35 billion and basic EPS of roughly a US$0.02 profit. Over recent periods, the company has seen quarterly revenue move in a tight band around the US$328 million to US$363 million range and basic EPS swing between a loss of about US$0.07 and a profit of roughly US$0.15. This leaves investors weighing modest top...
NYSE:NEXA
NYSE:NEXAMetals and Mining

Nexa Resources (NEXA) TTM Return To Profit Tests Bullish Margin Narratives

Nexa Resources (NYSE:NEXA) has wrapped up FY 2025 with fourth quarter revenue of US$903.0 million and basic EPS of US$0.38, setting a clear marker for how the year finished. The company has seen quarterly revenue range from US$627.1 million in Q1 2025 to US$903.0 million in Q4 2025, while basic EPS moved from US$0.09 in Q1 to US$0.52 in Q3 and US$0.38 in Q4, giving investors a fuller picture of how profitability has tracked alongside sales. With trailing twelve month EPS at US$1.00 and net...
NYSE:MPT
NYSE:MPTHealth Care REITs

FFO Recovery At Medical Properties Trust (MPW) Challenges Bearish Cash Flow Narratives

Latest Earnings Snapshot Medical Properties Trust (MPW) has wrapped up FY 2025 with fourth quarter revenue of US$294.5 million, basic EPS of US$0.03, and Funds From Operations of US$115.9 million, giving investors a cleaner read on cash based performance for a healthcare REIT. The company has seen revenue move from US$247.5 million in Q3 2024 to US$234.8 million in Q4 2024 and then to US$294.5 million in Q4 2025. Basic EPS shifted from a loss of US$0.69 in Q4 2024 to a loss of US$0.20 in Q1...